Iovance Biotherapeutics
Mr. Shew joined Iovance in July 2021. He is a leader in information technology (IT) for global, publicly traded, expansion-stage biopharmaceutical companies. He previously served as Chief Information Officer at Jazz Pharmaceuticals for nine years as the company grew 10-fold to become a $2B+ revenue global, multi-product commercial company. Earlier, he held IT roles of increasing responsibility at Codexis, CV Therapeutics (acquired by Gilead Sciences) and Genencor. Mr. Shew received a B.S. in Biochemistry from the University of California, Davis, and an M.B.A. from Santa Clara University.
This person is not in any offices
Iovance Biotherapeutics
6 followers
Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.